2020 is undoubtedly a breakthrough year for the medical AI industry. In just 7 months, artificial intelligence imaging software has successively won the three types of medical device certificates given by the State Drug Administration. BioMind is one of them. In June, this AI company received the first domestic AI “image-aided diagnosis” NMPA Class III certificate.
Immediately after August, BioMind, as a member of the consortium, won the bid for the only national medical artificial intelligence public platform project of the Ministry of Industry and Information Technology of the People’s Republic of China-“A Public Service Platform for Artificial Intelligence Aided Diagnosis for the Medical and Health Industry”, with a bid amount of 168 million yuan. The consortium units that jointly form this national project are: Huawei, China Mobile, PLA General Hospital (301 Hospital), Tiantan Hospital, Peking University First Hospital, Tongren Hospital, Peking University Cancer Hospital, Zhengzhou University First Affiliated Hospital, China Institute of Food and Drug test.
According to industry insiders, “the top-level lineup of powerful alliances demonstrates the country’s determination to build artificial intelligence in healthcare and serve the people.”
Why did the national medical AI-assisted diagnosis platform choose it?
In fact, it is not difficult to find the logic behind every step of BioMind after counting the development history of BioMind.
In December 2019, in accordance with the “Notice of the General Office of the Ministry of Industry and Information Technology on Printing and Distributing the List of Listed Units for the Key Tasks of the New Generation of Artificial Intelligence Industry Innovation” (Gongxin Dingke Han  No. 284), BioMind was launched as an opener Technical research on the project of “Medical Imaging Aided Diagnosis System”. It is reported that BioMind ranked first in this unveiling.
During the COVID-19 pandemic in 2020, BioMind, Tiantan Hospital, and PLA General Hospital have been struggling for 16 days and nights after receiving the special task of “Artificial Intelligence-assisted Diagnosis of COVID-19 Pneumonia” by the Ministry of Industry and Information Technology (Gongke Han  No. 66) , The rapid development of BioMind “new crown” pneumonia CT imaging AI qualitative auxiliary diagnosis system. For its outstanding contributions to the prevention and control of the epidemic, BioMind was awarded the “2020 New Crown Epidemic Prevention and Control Ministry of Industry and Information Technology Commendation Unit”.
In July this year, BioMind stood out among the 17 medical AI companies participating in the evaluation in the national “Pneumonia AI Image-Assisted Diagnosis Product Evaluation” organized by the Ministry of Industry and Information Technology and was commended.
At the same time, after fierce competition, BioMind, as a member unit of the consortium, successfully won the bid for the only national medical artificial intelligence platform project of the Ministry of Industry and Information Technology-“A Public Service Platform for Artificial Intelligence Aided Diagnosis for the Medical and Health Industry”. The consortium units participating in this national-level project include: Huawei, China Mobile, PLA General Hospital (301 Hospital), Tiantan Hospital, Peking University First Hospital, Tongren Hospital, Peking University Cancer Hospital, Zhengzhou University First Affiliated Hospital, China Institute of Food and Drug test.
The winning document stated: (This project) takes the lead and participates in the hospitals, and ranks among the world’s leading medical institutions in such disciplines as heart and lung, brain, eye, blood vessel, orthopedics, and oncology, while BioMind Technology Co., Ltd., Huawei, and China Mobile respectively It is a benchmark enterprise in the fields of medical artificial intelligence, cloud computing, chip design, and network communications. ”
In this national-level project, BioMind needs to play multiple roles in AI, big data and other fields: Based on multi-modal biomedical data, jointly develop a deep learning framework and a new generation of neural network algorithms with Huawei Technologies Co., Ltd., and lead the platform network Information security system construction, lead the research and development of medical artificial intelligence application products, participate in the formulation of artificial intelligence medical health national/industry standards (draft), and participate in the establishment of the clinical performance evaluation index system of artificial intelligence medical health products.
Really landing, promote the fair accessibility of national medical resources
It is not difficult to see that in this national-level project, the country is committed to promoting the fairness and accessibility of my country’s medical resources through artificial intelligence technology, thereby improving the health and well-being of the people.
The member units of the consortium not only “pinch the tip” in the field of subdivided diseases, but also have a clear division of labor: the PLA General Hospital takes the lead in completing the construction of artificial intelligence screening and auxiliary diagnosis systems for the heart, blood vessels, lungs, and breasts; Tiantan Hospital leads brain tumors , Cerebrovascular disease, stroke and other diseases; Peking University First Hospital takes the lead in the kidney and prostate fields; Peking University Cancer Hospital takes the lead in the gastrointestinal tumor field; Tongren Hospital takes the lead in the eye, ear, nose, and throat and other organ diseases; Zheng University First Affiliated Hospital takes the lead in blood , Orthopedics, uterus and other diseases.
BioMind is responsible for the research and development of artificial intelligence applications in the above diseases. In fact, BioMind has already worked hard around “breadth + depth”, devoted itself to truly solving clinical needs, and developing medical AI applications that are suitable for various clinical medical scenarios, practically solve doctors’ problems, and have real clinical value.
In terms of in-depth research and development, taking neurological diseases as an example, BioMind is the first in the world to realize CT/MRI imaging artificial intelligence-assisted diagnosis of neurological diseases, including brain tumors, small vessel diseases, strokes, and more than 60 kinds of diseases. The diagnosis accuracy rate is More than 90%, and the diagnosis accuracy rate of some diseases exceeds 96%. In October of this year, at the International Conference on Global Cerebrovascular Disease-the 6th Annual Conference of the Chinese Stroke Society and the Tiantan International Cerebrovascular Disease Conference, BioMind released another major breakthrough-“BioMind Artificial Intelligence-assisted Diagnosis System for Intracranial Aneurysms “, the specificity, accuracy and other performance indicators are better than the top international products of the same kind.
In terms of breadth, in fact, BioMind has already achieved the application of covering multiple parts of the body and multiple diseases in the field of medical AI-assisted diagnosis. The series of applications include: neurological diseases imaging AI (brain tumor, cerebral small vessel disease, stroke, etc.), lung diseases (including pneumonia classification, tuberculosis, lung cancer and other auxiliary diagnosis), cardiovascular and cerebrovascular diseases CTA/CTP/MRP, heart diseases MR, breast disease MRI, etc., have become AI applications that cover multiple parts of the body, such as the head, neck, heart, blood vessels, and breast, to accurately assist in the diagnosis of multiple diseases.
At the same time, BioMind has also developed the BioMind cerebrovascular disease clinical diagnosis and treatment auxiliary decision-making system, which assists doctors in the whole process of diagnosis, treatment, and prognosis. It helps doctors realize that from patient admission to discharge, it can be updated in real-time in the diagnosis and treatment guidelines and patient data. Make clinical decisions scientifically and reasonably based on the reference of
As a result, BioMind is based on the dimensions of “disease type + course of disease”, and implements the application of auxiliary diagnosis and treatment decision-making. By meeting more primary medical needs, it promotes the establishment of a national medical AI-assisted diagnosis system and improves the level of primary medical services. More high-quality medical resources will sink to the grassroots level to help hierarchical diagnosis and treatment and healthy China.
Three types of certificates have followed one after another. What is the difference between “imaging-aided diagnosis”?
In June this year, BioMind obtained the NMPA Class III certificate. This is the first medical AI software approved by the National Food and Drug Administration to be named “image-assisted diagnosis”.
In the second half of 2020, several medical AI companies have successively obtained NMPA Class III certificates, but according to the nomenclature announced by the approval, they include “assisted testing”, “assisted triage”, “computing software”, etc., and BioMind approved The three types of certificates passed were named “imaging-aided diagnosis.”
It is BioMind’s BioMind “Tianyizhi” intracranial tumor magnetic resonance imaging-assisted diagnosis software that has been approved for the first three types of “image-aided diagnosis” AI. Talking about how to truly realize the “assisted diagnosis” function, BioMind Chief Technology Officer Wu Zhenzhou said that the software does not stop at the early screening of diseases, but can make further accurate diagnosis of diseases. For example, it can accurately classify and diagnose brain tumors (such as meningioma, acoustic neuroma, medulloblastoma, glioma, etc.), and automatically generate a structured report to help doctors quickly diagnose, improve work efficiency, and improve diagnosis.
The solid product strength has helped BioMind successfully open the international market. In 2018, BioMind obtained product certifications from more than a dozen countries including the European Union CE, Singapore and other countries. The products are sold to Germany, Poland, Luxembourg, Singapore and other countries and regions.
This may give us some industry inspiration. In recent years, as national policies have become more active towards AI medical products, the industrialization prospects of medical AI have gradually become clear. “Sellers” can finally enter the market for legal sales. However, whether “buyers” are willing to pay the bill, the key is to look at “sellers.” Whether the products provided really meet the demand.
In other words, for medical AI products, obtaining the three types of certificates is only the first step in commercialization, and it is the key to truly have clinical value.
With the continuous advancement of the approval of the three types of medical AI certificates, it is not difficult to imagine that in the future, people will continue to get market-oriented admission tickets. But who can go to the end, the market will tell us the answer based on value.